# Illumina Accelerator

> Illumina Accelerator is a VC fund backing Biotechnology and Health Care. See 57 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 57
- Last investment: Jul 2026
- Lead investor: 77%
- Fund size: $40M
- Last fund: Feb 2015
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/illumina-accelerator
- Website: https://www.illumina.com/accelerator

Illumina Accelerator is a VC fund in San Francisco focused on Biotechnology and Health Care. At Illumina, we’re committed to unlocking the power of the genome, and we know we can’t do it alone. Illumina Accelerator is our way of accelerating innovation in the entrepreneurial community. With extensive mentorship, financial support, and access to sequencing systems, reagents, and lab space, we’ve created a dynamic genomic ecosystem to helpstartups launch. Together we’ll advance the solutions that will transform medicine and improve human health and beyond.

## Contacts

5 contacts available for Illumina Accelerator. Shizune tracks 5 team members at Illumina Accelerator. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/illumina-accelerator?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 33 | 58% |
| Health Care | 16 | 28% |
| Therapeutics | 10 | 18% |
| Bioinformatics | 6 | 11% |
| Health Diagnostics | 6 | 11% |

30 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 19 | 33% |
| Non-equity Assistance | 12 | 21% |
| Convertible Note | 8 | 14% |
| Pre-Seed | 3 | 5% |
| Venture - Series Unknown | 1 | 2% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 21 | 37% |
| United Kingdom | 6 | 11% |
| Israel | 3 | 5% |
| India | 1 | 2% |
| Canada | 1 | 2% |

10 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Amanda Cashin | Co-Founder & Global Head of Illumina For Startups & Illumina Accelerator | 31 | — |
| Charles Dadswell | Senior Vice President & General Counsel | 0 | — |
| Marc Stapley | Executive Vice President, Chief Administrative Officer, and Chief Financial Officer | 0 | — |
| Omead Ostadan | Executive Vice President, Operations, Products & Strategy | 0 | — |
| Richard Klausner | Chief Medical Officer & Interim General Manager, Oncology | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Juno Bio | Juno Bio uses machine learning and state of the art bioinformatics to analyse and predict how best to manipulate microbiomes, significantly reducing the time and resources needed to improve their functionality. | $3.8M | Venture - Series Unknown | Jul 16, 2026 |  |
| Viridian Seeds | Viridian Seeds creates super-legumes to provide a sustainable source of healthy, nutritious plant proteins. |  | Seed | Sep 14, 2022 |  |
| Viridian Seeds | Viridian Seeds creates super-legumes to provide a sustainable source of healthy, nutritious plant proteins. |  | Seed | Sep 14, 2022 |  |
| Pandora Biosciences | Pandora Biosciences operates as a neuroscience company. |  | Non-equity Assistance | Sep 14, 2022 |  |
| Pandora Biosciences | Pandora Biosciences operates as a neuroscience company. |  | Non-equity Assistance | Sep 14, 2022 |  |
| Terrapeutics Pharma | Terrapeutics Pharma develops a drug discovery platform that is based on a groundbreaking technology. |  | Non-equity Assistance | Sep 14, 2022 |  |
| Terrapeutics Pharma | Terrapeutics Pharma develops a drug discovery platform that is based on a groundbreaking technology. |  | Non-equity Assistance | Sep 14, 2022 |  |
| Acrobat Genomics | Acrobat Genomics uses its unique high-throughput CRISPR gene editing precision technology to create a pipeline of new therapies. |  | Non-equity Assistance | Sep 14, 2022 |  |
| Acrobat Genomics | Acrobat Genomics uses its unique high-throughput CRISPR gene editing precision technology to create a pipeline of new therapies. |  | Non-equity Assistance | Sep 14, 2022 |  |
| Dama Health | Dama Health offers insights into unique predispositions, efficacy, and side effect profiles. Dama Health uses genetic testing and an automated matching system to match individuals to the best options for their unique needs. |  | Non-equity Assistance | Sep 14, 2022 |  |

10 of 57 investments shown.

## Co-investors
- [First In Ventures](https://shizune.co/investors/profile/first-in-ventures) — VC Fund, 3 deals together
- [Axial VC](https://shizune.co/investors/profile/axial-vc) — VC Fund, 2 deals together
- [Hyphen Capital](https://shizune.co/investors/profile/hyphen-capital) — VC Fund, 2 deals together
- Rhythm VC — VC Fund, 2 deals together
- Saba Investments — VC Fund, 2 deals together
- [UpHonest Capital](https://shizune.co/investors/profile/uphonest-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Illumina Accelerator invest in?

Illumina Accelerator invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Non-equity Assistance stage. Most of the 57 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Illumina Accelerator?

Public channels for Illumina Accelerator include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Illumina Accelerator?

The team at Illumina Accelerator includes Amanda Cashin (Co-Founder & Global Head of Illumina For Startups & Illumina Accelerator), Charles Dadswell (Senior Vice President & General Counsel) and Marc Stapley (Executive Vice President, Chief Administrative Officer, and Chief Financial Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co